A case series by Mason and Young [65] described 2 cases of infants who were <12 months commencing emicizumab: one started at 7 days old following initial treatment of intracranial hemorrhage with a FVIII infusion, and the other commenced at 5 weeks due to parental anxiety regarding the potential for intracranial hemorrhage during infancy. This evidence concerns the gene F8 and intracranial hemorrhage.